DELCATH SYSTEMS, INC. (DCTH)

Cancer of the liver sits trapped in a constraint: the liver receives one of the body’s richest blood supplies, bringing toxins and drugs to destroy the tumor. But those same toxins and drugs poison the rest of the body. The oncologist’s dilemma is ancient—how to deluge the tumor without poisoning the patient. DELCATH SYSTEMS, INC. (DCTH) intervenes at the point where blood enters the liver, isolating that organ temporarily from the body’s circulation and exposing the tumor to high doses of chemotherapy while the body is shielded from systemic toxicity.

The Drug-Delivery Problem in Liver Cancer

Liver cancer, whether primary hepatocellular carcinoma or metastatic tumors seeded to the liver, is notoriously difficult to treat. Surgery removes tumors that can be excised, but many patients present with multifocal disease or tumors too close to critical blood vessels for safe resection. Systemic chemotherapy—drugs infused into the arm to circulate throughout the body—has limited efficacy in liver cancer and exposes patients to organ damage, hair loss, and immune suppression.

The liver’s anatomy creates an opportunity. The organ receives blood through two sources: the hepatic artery, which delivers nutrient-rich blood from the abdominal aorta, and the portal vein, which brings nutrient-depleted blood from the gastrointestinal tract. A surgeon can occlude these vessels temporarily, isolating the liver from the body’s circulation. During that isolated window, high-dose chemotherapy can be infused directly into the liver’s blood supply, bathing the tumor in cytotoxic drugs while those drugs are trapped within the organ.

The drug is then filtered out by the liver before returning to the body’s systemic circulation. The patient receives a fraction of the systemic dose that would normally cause severe side effects.

The DELCATH Isolation and Perfusion System

DELCATH’s device orchestrates this isolation and delivery. The system includes catheters that block the hepatic artery and portal vein, isolating the liver. Separate infusion lines deliver chemotherapy directly into the hepatic circulation at high concentration. A filtration circuit—the company’s proprietary innovation—filters out the chemotherapy before blood exits the liver back into the body.

The filtration step is critical. Without it, chemotherapy that accumulated in liver-derived blood would re-enter the systemic circulation as the isolation is released, defeating the purpose. DELCATH’s filter mechanism captures the drug (typically melphalan, a nitrogen-mustard chemotherapy), allowing doctors to deliver doses 10–20 times higher than would be tolerated systemically.

The procedure is an operating-room surgery. An interventional radiologist or surgeon places catheters under imaging guidance, confirms isolation, initiates perfusion and filtration, and manages the technical equipment during the procedure. Once the infusion is complete, catheters are withdrawn and blood flow to the liver is restored.

Position in the Interventional Oncology Supply Chain

DELCATH sits between the oncology care team and the patient with advanced liver cancer. The company does not determine who receives treatment (that is the physician’s decision), nor does it manage the patient’s broader cancer care. Instead, it provides the specialized apparatus that makes one particular treatment approach possible.

The supply chain looks like this: the patient is diagnosed with liver cancer and deemed a candidate for isolated hepatic perfusion. The physician discusses the procedure with the patient and, if both agree, prepares for an operating-room surgery. The hospital obtains DELCATH’s equipment (either as a purchase or, in many cases, as a single-use system purchased per procedure). The procedure is performed. The system is used once and discarded (or refurbished and resold).

Revenue flows from the hospital or physician’s office purchasing the device. Prices for single-use oncology devices can range from thirty thousand to over one hundred thousand dollars per procedure, depending on the system’s complexity and regulatory positioning.

What DELCATH Adds

The company adds an enabling technology—a bridge between the wish to deliver high-dose chemotherapy and the ability to do so safely. Without DELCATH’s system, doctors would have to decide between offering lower-dose systemic chemotherapy (less effective but safer) or hepatic resection (more invasive but sometimes curative).

The isolated hepatic perfusion approach splits the difference. It allows high-dose drug delivery with lower systemic exposure, theoretically improving response rates compared to standard chemotherapy while avoiding the morbidity of major surgery.

Clinical Adoption and Regulatory Context

The procedure is rare globally. Unlike common oncology interventions (infusion of intravenous chemotherapy, radiation therapy), hepatic perfusion requires specialized surgical skill and hospital infrastructure. Adoption has been slow because the learning curve is steep and the patient population is limited.

Regulatory approval is essential. DELCATH holds FDA clearance for its device and has pursued clinical trials to generate evidence of efficacy compared to alternative treatments. Study results inform whether insurers will reimburse the procedure and whether physicians will adopt it.

The company’s value depends on clinical evidence that the procedure improves outcomes. If trials show benefit—longer survival or longer time-to-progression—reimbursement is more likely and adoption accelerates. If trials show no benefit or unexpected toxicity, demand collapses.

Market Size and Economics

Hepatocellular carcinoma is a global health burden, particularly in regions with high rates of hepatitis B and C. Yet isolated hepatic perfusion is available in only a handful of centers worldwide. Market potential is large in theory but constrained by adoption barriers.

In the United States, the addressable market includes patients with unresectable intrahepatic cholangiocarcinoma, colorectal cancer metastatic to the liver, or hepatocellular carcinoma who are not candidates for standard surgery or systemic chemotherapy. Estimates suggest hundreds of eligible patients annually, translating to tens of millions in potential annual revenue at scale.

But “at scale” is contingent. The procedure must diffuse to more hospitals, and more surgeons must acquire the skill to perform it safely. DELCATH must maintain clinical leadership and evidence generation to drive adoption.

Competitive Landscape and Substitutes

DELCATH competes indirectly with other localized liver cancer treatments: transarterial chemoembolization (TACE), where chemotherapy-laden beads are threaded into the hepatic artery and lodge in the tumor’s blood supply; ablation (freezing or heating the tumor to destroy it); and hepatic resection (surgical removal). Each has different indications, recovery profiles, and evidence bases.

DELCATH’s advantage is the filtration step, which theoretically allows higher drug concentrations than TACE while preserving normal liver tissue better than ablation. The disadvantage is procedural complexity and the requirement for operative-room infrastructure.

Why the Supply Chain Exists

Isolated hepatic perfusion exists because some patients with liver cancer have exhausted other options. They are too sick for major surgery or have tumors in locations where resection would destroy too much healthy tissue. Standard chemotherapy has failed or is contraindicated by liver dysfunction. These patients need alternatives.

DELCATH provides an alternative by channeling chemotherapy directly to the tumor while filtering out systemic toxicity. The company’s value is conditional on three things: that the procedure is technically safe, that it improves patient outcomes relative to existing treatments, and that hospitals find it economically viable to maintain the expertise and equipment required.

Ongoing Challenges

The company faces low procedure volume and long sales cycles. Each hospital that adopts the procedure requires training, credentialing, and sustained utilization to maintain proficiency. A hospital where the procedure is performed a handful of times per year may not keep the necessary skills sharp.

DELCATH must continuously generate clinical evidence and support education to drive adoption. Cash burn is significant for a device company with limited revenue. The company’s survival depends on whether the procedure proves to be a durable, reimbursed standard-of-care approach to a meaningful portion of patients with hepatic malignancy.